logo
Plus   Neg
Share
Email

Pfizer, Sangamo: Follow-up Data Affirm Findings Of Phase 1/2 Giroctocogene Fitelparvovec Study

Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO) announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with severe hemophilia A. The results showed sustained factor VIII activity levels and no bleeding events or factor usage in 3e13 vg/kg cohort following the Gene Therapy. Giroctocogene fitelparvovec was generally well tolerated.

"We are excited that these data affirm previous findings from this Phase 1/2 study, and that all five patients have sustained levels of factor VIII activity with no bleeding events or use of factor replacement therapy. The Phase 3 lead in study is ongoing," said Seng Cheng, Chief Scientific Officer of Pfizer's Rare Disease Research Unit.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Former Google engineer Anthony Levandowski was sentenced by a U.S. judge to eighteen months in prison for stealing trade secrets from Google's self-driving car unit before he defected to Uber's rival unit. Levandowski admitted that from 2009 to 2016, he worked in Google's self-driving car program, known then as Project Chauffer. JetBlue has strengthened its face covering policy, by prohibiting face masks with vents or exhalation valves, starting August 10. It will also no longer allow customers to claim exemptions from wearing a face covering altogether. Home Depot, Inc. is set to open three new distribution centers in Georgia over the next 18 months, which is expected to create an additional 1,000 new jobs in Greater Atlanta, including full-time and part-time positions. The home improvement retailer has already created more than 5,000 new jobs in Georgia over the last five years.
Follow RTT